When focusing on ER+ breast cancer only (30 ER+/HER2− [human epidermal growth factor receptor 2], 1 ER+/HER2 unknown), we also observed a trend toward MYC amplification enrichment in non-responding patients (Fig. 9 B). Here, ERBB2 is linked to breast carcinoma.